Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
ChiCTR2100054220Phase 4Recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tofacitinib in Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD) (2 arms), sponsored by Yantai Yuhuangding Hospital. Primary endpoints: Disease activity score 28-joint count CRP (DAS28-CRP), Pulmonary function test (PFT) and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
03
Conditions
Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD)
Beyond the preview
Go deeper on ChiCTR2100054220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054220.